Atrofia cerebelosa y uso crónico de fenitoína. Revisión de la literatura y presentación de un caso clínico
Fuente:
Redalyc
Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | es |
| Published: |
Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile
2012
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1876477360672342016 |
|---|---|
| author | Patricia Guirao-Bringas |
| author_facet | Patricia Guirao-Bringas |
| contents | Atrofia cerebelosa y uso crónico de fenitoína. Revisión de la literatura y presentación de un caso clínico Patricia Guirao-Bringas Gustavo Díaz-Pérez Medicina Athrophy epilepsy toxicity phenytoin cerebellum Introduction: The most important chronic toxic adverse effect caused by phenytoin takes place in the cerebellum and may lead to irre versible cerebellar atrophy. Objective: Draw attention to the occurrence of cerebellar atrophy in patients undergoing long-term phenitoyn therapy Emphasize the need for and feasibility of early diagnosis. Update pathogenetic hypotheses. Development: Brief history of Phenytoin since it was fi rst used in the treatment of epileptic seizures; acute, subacute, and chronic adverse effects, with emphasis on cerebe llar atrophy. The case presented developed during long-term phenytoin treatment of an epileptic patient. The hypotheses so far raised on pathophysiological mechanisms involved in causing atrophy are described. Complete current review of literature is included and most relevant authors are listed. Conclusions: Cerebellar atrophy following long-term phenytoin therapy takes place in a minor, as yet indeterminate, number of patients; its occurrence, however, must be borne in mind in the case of patients under long-term therapy. CT and MR contributions to early diagnosis are underlined, as well as the current and potential support of new neuroimaging techniques. Recent hypotheses regarding pathophysiological mechanisms involved, direct toxic action, anoxia, and dysafferentation are discussed. The debate on future use of phenytoin as fi rst-line drug is supported. 2012 artículo científico 0034-7388 https://www.redalyc.org/articulo.oa?id=331527728005 es http://www.redalyc.org/revista.oa?id=3315 Revista Chilena de Neuropsiquiatría application/pdf Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile Revista Chilena de Neuropsiquiatría (Chile) Num.1 Vol.50 |
| format | Artículo científico |
| id | redalyc_331527728005 |
| institution | Redalyc |
| language | es |
| publishDate | 2012 |
| publisher | Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile |
| spellingShingle | Atrofia cerebelosa y uso crónico de fenitoína. Revisión de la literatura y presentación de un caso clínico Patricia Guirao-Bringas Medicina Athrophy epilepsy toxicity phenytoin cerebellum Atrofia cerebelosa y uso crónico de fenitoína. Revisión de la literatura y presentación de un caso clínico Patricia Guirao-Bringas Gustavo Díaz-Pérez Medicina Athrophy epilepsy toxicity phenytoin cerebellum Introduction: The most important chronic toxic adverse effect caused by phenytoin takes place in the cerebellum and may lead to irre versible cerebellar atrophy. Objective: Draw attention to the occurrence of cerebellar atrophy in patients undergoing long-term phenitoyn therapy Emphasize the need for and feasibility of early diagnosis. Update pathogenetic hypotheses. Development: Brief history of Phenytoin since it was fi rst used in the treatment of epileptic seizures; acute, subacute, and chronic adverse effects, with emphasis on cerebe llar atrophy. The case presented developed during long-term phenytoin treatment of an epileptic patient. The hypotheses so far raised on pathophysiological mechanisms involved in causing atrophy are described. Complete current review of literature is included and most relevant authors are listed. Conclusions: Cerebellar atrophy following long-term phenytoin therapy takes place in a minor, as yet indeterminate, number of patients; its occurrence, however, must be borne in mind in the case of patients under long-term therapy. CT and MR contributions to early diagnosis are underlined, as well as the current and potential support of new neuroimaging techniques. Recent hypotheses regarding pathophysiological mechanisms involved, direct toxic action, anoxia, and dysafferentation are discussed. The debate on future use of phenytoin as fi rst-line drug is supported. 2012 artículo científico 0034-7388 https://www.redalyc.org/articulo.oa?id=331527728005 es http://www.redalyc.org/revista.oa?id=3315 Revista Chilena de Neuropsiquiatría application/pdf Sociedad de Neurología, Psiquiatría y Neurocirugía de Chile Revista Chilena de Neuropsiquiatría (Chile) Num.1 Vol.50 |
| title | Atrofia cerebelosa y uso crónico de fenitoína. Revisión de la literatura y presentación de un caso clínico |
| topic | Medicina Athrophy epilepsy toxicity phenytoin cerebellum |
| url | https://www.redalyc.org/articulo.oa?id=331527728005 |